Table 3.
Treatment Status by Prescription (by Study Year) or Gynecologic Procedure (Year 1 Only), Patients with UF-HMB and UF-only
| Treatment, n (%) | UF-HMB (n = 66,313) | UF-only (n = 26,068) |
|---|---|---|
| Use of any pharmacologic treatment of interest | ||
| Year 1 | 30,017 (45.3) | 9,085 (34.9) |
| Year 2 | 35,579 (53.7) | 10,993 (42.2) |
| Anytime | 42,617 (64.3) | 13,254 (50.8) |
| Use of any hormonala treatment | ||
| Year 1 | 24,526 (37.0) | 7,606 (29.2) |
| Year 2 | 28,876 (43.5) | 9,063 (34.8) |
| Anytime | 34,713 (52.3) | 10,771 (41.3) |
| Any gynecologic procedure of interest (year 1) | 32,819 (49.5) | 7,311 (28.0) |
| Hysterectomy | 20,499 (30.9) | 4,326 (16.6) |
| Other procedures | 16,029 (24.2) | 3,562 (13.7) |
a
Hormonal treatment includes aromatase inhibitors, leuprolide, other luteinizing hormone-releasing hormone agonists, elagolix, estrogen, progestin, nonoral hormonal contraceptives (except for ParaGard® copper intrauterine device J73000, NDC 51285020401, 51285020402), and oral hormonal contraceptives.